What's Happening?
Obesity has overtaken oncology as the largest contributor to the biopharma pipeline value, according to a recent analysis by Deloitte. This marks the first time in 16 years that cancer has not held the top spot. The report highlights the rapid emergence
of obesity as a significant market, with its share of the pipeline value increasing to 25% in 2025, compared to oncology's 20%. The shift is largely driven by the success of GLP-1/GIP receptor agonists, which have significantly boosted forecast peak sales per asset. Eli Lilly and Novo Nordisk are identified as the leading companies in the obesity drug market. The report also notes a rise in the cost of developing a single asset, which reached $2.67 billion in 2025.
Why It's Important?
The shift in pipeline value from oncology to obesity reflects a broader trend in the pharmaceutical industry towards addressing chronic conditions with high prevalence and unmet needs. The focus on obesity, a condition affecting millions globally, indicates a potential for significant market growth and innovation in treatment options. This change could lead to increased investment in obesity research and development, potentially resulting in new therapies that improve patient outcomes. However, the concentration of value in a few blockbuster drugs also poses risks, as failure of a single program could lead to substantial financial losses. The industry's reliance on a small number of high-value assets underscores the need for diversification and innovation in drug development.
What's Next?
As the obesity market continues to grow, companies like Eli Lilly and Novo Nordisk are expected to intensify their efforts to maintain leadership positions. The competition may drive further advancements in drug formulations and delivery methods, potentially leading to more effective and accessible treatments. Other pharmaceutical companies, such as Pfizer and Roche, are also likely to increase their investments in obesity research to capture a share of this lucrative market. Regulatory approvals and clinical trial outcomes will play a crucial role in shaping the future landscape of obesity treatments. Additionally, the industry's focus on novel mechanisms of action may lead to breakthroughs in other therapeutic areas.
